ALKYLAMINE

- Alkyl Amines Chemicals Limited clarified that it has made all necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. - The company stated it has no pending information or announcements that could explain the significant increase in trading volume across exchanges. - The management is unaware of any specific trigger for the recent price or volume movement.

- Trading window closed effective October 1, 2026 for designated persons. - Closure is for consideration of Unaudited Financial Results for quarter and half year ending September 30, 2026. - Trading window will reopen 48 hours after result declaration.

- Alkyl Amines Chemicals Limited announced the results of its Postal Ballot, with all five special resolutions passed by members with the requisite majority on September 19, 2026. - Resolutions include the re-designation of Mr. Yogesh M. Kothari as Executive Chairman, Mr. Kirat M. Patel and Mr. Suneet Y. Kothari as Joint Managing Directors, effective October 1, 2026. - Mr. Rakesh Goyal was re-designated and appointed as Executive Director (Operations) for five years from April 1, 2027. - Authorization for payment of commission to Non-Executive Directors for five years from April 1, 2027 was also passed.

- Alkyl Amines Chemicals Limited allotted 2,047 equity shares (face value Rs. 2/-) to eligible employees under ESOP 2018 on September 17, 2026. - Paid-up equity share capital increased to Rs. 10,22,96,448/-. - Exercise prices for these shares ranged from Rs. 1,040/- to Rs. 2,000/-.

- Postal Ballot for re-designation of Mr. Yogesh M. Kothari as Executive Chairman (Oct 2026 - Mar 2030). - Re-designation of Mr. Kirat M. Patel and Mr. Suneet Y. Kothari as Joint Managing Directors (Oct 2026 - Dec 2029). - Re-designation and appointment of Mr. Rakesh Goyal as Executive Director (Operations) for 5 years (April 2027 - March 2032). - Authorization for payment of commission to Non-Executive Directors for 5 years from April 2027. - E-voting period: August 21, 2026 to September 19, 2026.

- Standalone Revenue ₹528.01 Cr vs ₹405.53 Cr (▲30.2% YoY) - EBITDA ₹133.60 Cr vs ₹76.57 Cr (▲74.5% YoY) - PAT ₹94.63 Cr vs ₹49.44 Cr (▲91.4% YoY) - EBITDA Margin 25.30% vs 18.88% (▲642bps) - Board approved re-designations of Mr. Yogesh M. Kothari as Executive Chairman, and Mr. Kirat M. Patel & Mr. Suneet Y. Kothari as Joint Managing Directors. - Mr. Rakesh Goyal was re-designated and appointed as Executive Director - Operations for five years. - Mr. Rakesh Goyal has pending criminal and civil cases for alleged financial irregularities from previous employment at National Peroxide Limited.

- Consolidated Revenue ₹528.01 Cr vs ₹405.53 Cr (▲30.2% YoY) - EBITDA ₹133.60 Cr vs ₹76.57 Cr (▲74.5% YoY) - PAT ₹94.63 Cr vs ₹49.44 Cr (▲91.4% YoY) - EBITDA Margin 24.86% vs 18.52% (▲634bps) - Board approved re-designation of Mr. Yogesh M. Kothari as Executive Chairman, Mr. Kirat M. Patel and Mr. Suneet Y. Kothari as Joint Managing Directors, effective October 1, 2026. - Mr. Rakesh Goyal re-designated and appointed as Executive Director - Operations for 5 years from April 1, 2027. - Board approved payment of commission to Non-Executive Directors, not exceeding 1% of net profits, for 5 years from FY27.

New Filing detected. See link for details.

- 46th Annual General Meeting (AGM) held on July 3, 2026. - Members approved a dividend of Rs. 10/- per share for the financial year ended March 31, 2026. - Mr. Premal N. Kapadia was re-appointed as Director. - Company is evaluating CAPEX for expansion and expects positive impact from anti-dumping duty on Acetonitrile.

- Alkyl Amines Chemicals allotted 2,125 equity shares of ₹2/- each to eligible employees under the ESOP 2018 scheme, approved by the Nomination and Remuneration Committee on June 16, 2026. - Post-allotment, the company's paid-up equity share capital increased from ₹10,22,88,104/- to ₹10,22,92,354/-, comprising 5,11,46,177 equity shares.

New Filing detected. See link for details.

New Filing detected. See link for details.

New Filing detected. See link for details.